(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 March 2013 (07.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/030032 A1

(51) International Patent Classification:
G01N 33/68 (2006.01)

(21) International Application Number:
PCT/EP2012/066216

(22) International Filing Date:
21 August 2012 (21.08.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11179058.0 26 August 2011 (26.08.2011) EP
12164017.1 13 April 2012 (13.04.2012) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ESSIOUX, Laurent** [FR/FR]; 6 rue Charles de Gaulle, F-68220 Attenschwiller (FR). **HORN, Carsten** [DE/CH]; Im Burgfelderhof 43, CH-4055 Basel (CH). **KARL, Johann** [DE/DE]; Bert-Schratzlseer-Strasse 7, 82380 Peissenberg (DE). **KASTNER, Peter** [DE/DE]; Helene-Lange-Weg 27, 80637 Muenchen (DE). **MODEL, Fabian** [DE/DE]; Ponholzweg 6, 82377 Penzberg (DE). **PALERMO, Giuseppe** [IT/CH]; Wettsteinallee 76, CH-4058 Basel (CH). **RABE, Christina** [DE/DE]; Unterenzenau 3, 83670 Bad Heilbrunn (DE). **UMBRICHT, Daniel** [CH/CH]; Ampèrestrasse 3, CH-8037 Zuerich (CH). **VARGAS, Gabriel** [US/US]; 2746 Conejo Canyon Court, Apt 15, Thousand Oaks, CA 91362 (US). **VOGT, Anne** [DE/DE]; Pestalozzistrasse 66, 79540 Loerrach (DE).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: A METHOD FOR PREDICTING CLINICAL BENEFIT IN THE TREATMENT OF NEURODEVELOPMENTAL, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS

FIGURE 3



(57) Abstract: The invention relates to an in vitro method of predicting a response for patients, having neurodevelopmental, neurological or neuropsychiatric disorders, if treated with a compound, targeting the glutamatergic pathway, comprising the steps i) determining the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof in a sample of a patient, ii) comparing the protein concentration determined in step i) to a value representative of the protein concentration of one, two three, four, five or six members of complement factor H family in patients, having neurodevelopmental, neurological or neuropsychiatric disorders, iii) wherein a higher protein concentration of one, two three, four five or six members from complement factor H family in the sample of the patient having neurodevelopmental, neurological or neuropsychiatric disorders is indicative for a patient who will derive clinical benefit from this treatment and iv) selecting this treatment for patients having neurodevelopmental, neurological or neuropsychiatric disorders.

WO 2013/030032 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*